Propranolol

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Alprazolam and Propranolol Hydrochloride is a synergistic psychotropic-cardiovascular formulation combining a triazolobenzodiazepine with a non-selective beta-adrenergic blocker. Alprazolam enhances central inhibitory GABAergic neurotransmission at the GABAA receptor, relieving psychological panic and tension, while propranolol competitively antagonizes peripheral beta-1 and beta-2 adrenergic receptors, curbing somatic autonomic manifestations of anxiety (palpitations, resting tachycardia, tremors, sweating). Indicated for situational anxiety, panic disorder with severe autonomic hyperactivity, and performance anxiety.

Alprazolam and Propranolol Hydrochloride is a synergistic psychotropic-cardiovascular formulation combining a triazolobenzodiazepine with a non-selective beta-adrenergic blocker. Alprazolam enhances central inhibitory GABAergic neurotransmission at the GABAA receptor, relieving psychological panic and tension, while propranolol competitively antagonizes peripheral beta-1 and beta-2 adrenergic receptors, curbing somatic autonomic manifestations of anxiety (palpitations, resting tachycardia, tremors, sweating). Indicated for situational anxiety, panic disorder with severe autonomic hyperactivity, and performance anxiety.

Etizolam and Propranolol is a psychotropic and autonomic regulator combination pairing a thienodiazepine with a non-selective beta-blocker. Etizolam acts as a full agonist at central GABAA receptors to suppress emotional distress and anticipatory anxiety, while propranolol blocks peripheral beta-adrenergic receptors to eliminate somatic symptoms (tachycardia, palpitations, sweating, tremors). Indicated for situational anxiety, autonomic anxiety manifestations, panic disorder, and tension headache.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Etizolam and Propranolol is a psychotropic and autonomic regulator combination pairing a thienodiazepine with a non-selective beta-blocker. Etizolam acts as a full agonist at central GABAA receptors to suppress emotional distress and anticipatory anxiety, while propranolol blocks peripheral beta-adrenergic receptors to eliminate somatic symptoms (tachycardia, palpitations, sweating, tremors). Indicated for situational anxiety, autonomic anxiety manifestations, panic disorder, and tension headache.

Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.

Clonazepam and Propranolol is a psychotropic and autonomic regulator combination. Clonazepam provides sustained central anxiolysis and neuronal stabilization via GABAA chloride conductance, while propranolol blocks peripheral beta-adrenergic receptors, stopping autonomic hyperarousal (tremors, racing heartbeat, flushing). Indicated for social phobia, severe panic attacks, stage fright, and anxiety disorders characterized by palpitations and tremor.

Clonazepam and Propranolol is a psychotropic and autonomic regulator combination. Clonazepam provides sustained central anxiolysis and neuronal stabilization via GABAA chloride conductance, while propranolol blocks peripheral beta-adrenergic receptors, stopping autonomic hyperarousal (tremors, racing heartbeat, flushing). Indicated for social phobia, severe panic attacks, stage fright, and anxiety disorders characterized by palpitations and tremor.

Clonazepam and Propranolol is a psychotropic and autonomic regulator combination. Clonazepam provides sustained central anxiolysis and neuronal stabilization via GABAA chloride conductance, while propranolol blocks peripheral beta-adrenergic receptors, stopping autonomic hyperarousal (tremors, racing heartbeat, flushing). Indicated for social phobia, severe panic attacks, stage fright, and anxiety disorders characterized by palpitations and tremor.